EP0871463B2 - Regulation du comportement alimentaire - Google Patents

Regulation du comportement alimentaire Download PDF

Info

Publication number
EP0871463B2
EP0871463B2 EP96918064A EP96918064A EP0871463B2 EP 0871463 B2 EP0871463 B2 EP 0871463B2 EP 96918064 A EP96918064 A EP 96918064A EP 96918064 A EP96918064 A EP 96918064A EP 0871463 B2 EP0871463 B2 EP 0871463B2
Authority
EP
European Patent Office
Prior art keywords
mch
cell
subject
treatment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96918064A
Other languages
German (de)
English (en)
Other versions
EP0871463B1 (fr
EP0871463A1 (fr
EP0871463A4 (fr
Inventor
Eleftheria Maratos-Flier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joslin Diabetes Center Inc
Original Assignee
Joslin Diabetes Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23877870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0871463(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Joslin Diabetes Center Inc filed Critical Joslin Diabetes Center Inc
Publication of EP0871463A1 publication Critical patent/EP0871463A1/fr
Publication of EP0871463A4 publication Critical patent/EP0871463A4/fr
Application granted granted Critical
Publication of EP0871463B1 publication Critical patent/EP0871463B1/fr
Publication of EP0871463B2 publication Critical patent/EP0871463B2/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Claims (19)

  1. Utilisation de la MCH ou un agoniste de celle-ci dans la préparation d'un médicament pour une méthode pour promouvoir l'appétit ou gagner du poids ou maintenir le poids corporel chez un sujet, comprenant l'administration d'une quantité efficace de MCH ou un agoniste de celle-ci audit sujet, dans laquelle l'agoniste est un peptide analogue de la MCH.
  2. Utilisation selon la revendication 1, où ledit sujet a un poids corporel insuffisant ou présente un appétit inférieur à la normale.
  3. Utilisation selon la revendication 1, où ledit sujet souffre d'anorexie mentale.
  4. Utilisation selon la revendication 1, où ledit sujet subit actuellement ou a subi un traitement qui a comme conséquence la diminution de l'appétit.
  5. Utilisation selon la revendication 1, comprenant en outre un diagnostic dudit sujet comme étant à risque pour tout comportement nutritionnel anormal, maigreur ou tout trouble d'ordre alimentaire.
  6. Utilisation selon la revendication 1, où ledit sujet est un être humain.
  7. Utilisation selon la revendication 1, où il est administré audit sujet une deuxième dose de MCH ou un agoniste de celle-ci, dans laquelle l'agoniste est un peptide analogue de la MCH.
  8. Utilisation d'un antagoniste de la MCH dans la préparation d'un médicament pour une méthode destinée à inhiber l'appétit ou le gain de poids chez un sujet, comprenant l'administration audit sujet d'une quantité efficace d'un antagoniste de la MCH, dans laquelle l'antagoniste est un peptide analogue de la MCH qui se lie à un récepteur de la MCH.
  9. Utilisation selon la revendication 8, où ledit sujet souffre d'une surcharge pondérale ou présente un comportement obsessionnel vis-à-vis de l'alimentation.
  10. Utilisation selon la revendication 8, diagnostiquant en outre ledit sujet comme étant à risque pour tout comportement obsessionnel vis-à-vis de l'alimentation, pour obésité ou pour tout trouble de l'alimentation.
  11. Utilisation selon la revendication 8, où ledit sujet est un être humain
  12. Utilisation selon la revendication 8, où sur ledit sujet on administre une deuxième dose d'antagoniste de la MCH
  13. Utilisation selon la revendication 8, où ledit antagoniste est un peptide analogue de la MCH ayant au moins 70 % d'homologie avec la MCH
  14. Méthode d'évaluation d'un traitement quant à ses effets sur le comportement nutritionnel, consistant : à administrer le traitement à un système d'essai basé sur un mélanocyte dans une préparation de culture de cellule ; à déterminer si des changements se sont produits dans ledit système, et à administrer le traitement à un deuxième système de test et à déterminer l'effet du traitement sur un paramètre en relation avec le comportement nutritionnel, avec l'augmentation ou la perte de poids dans le deuxième système, dans laquelle le traitement est un peptide analogue de la MCH.
  15. Méthode selon la revendication 14, où ledit traitement est un polypeptide ayant au moins 50% d'homologie avec la MCH.
  16. Méthode d'évaluation du traitement quant à ses effets sur le comportement nutritionnel consistant : à disposer d'une cellule ou d'une préparation de cellules de culture, ayant un gène rapporteur lié à la région promoteur de la MCH ; à administrer ledit traitement et à déterminer si un effet sur l'expression du gène rapporteur a eu lieu.
  17. Méthode selon la revendication 16, où ledit traitement consiste en l'administration d'un agent et que ledit agent est un polysaccharide, un acide nucléique, un polypeptide gras ou un peptide mimétique.
  18. Méthode selon la revendication 16, où ledit agent est un polypeptide ayant au moins 50% d'homologie avec la MCH.
  19. Méthode pour évaluer un traitement pour ses effets sur le comportement nutritionnel, l'appétit ou le maintien du poids corporel consistant : à disposer d'une cellule ou d'une préparation en culture de cellule ; à administrer le traitement à la cellule ou à la préparation en culture de cellule et à déterminer si un effet sur l'ARN de la MCH ou sur les niveaux de protéines a eu lieu.
EP96918064A 1995-06-06 1996-06-05 Regulation du comportement alimentaire Expired - Lifetime EP0871463B2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/473,022 US5849708A (en) 1995-06-06 1995-06-06 Promotion of eating behavior
US473022 1995-06-06
PCT/US1996/008798 WO1996039162A1 (fr) 1995-06-06 1996-06-05 Regulation du comportement alimentaire

Publications (4)

Publication Number Publication Date
EP0871463A1 EP0871463A1 (fr) 1998-10-21
EP0871463A4 EP0871463A4 (fr) 1999-09-08
EP0871463B1 EP0871463B1 (fr) 2003-02-05
EP0871463B2 true EP0871463B2 (fr) 2007-11-21

Family

ID=23877870

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96918064A Expired - Lifetime EP0871463B2 (fr) 1995-06-06 1996-06-05 Regulation du comportement alimentaire

Country Status (8)

Country Link
US (2) US5849708A (fr)
EP (1) EP0871463B2 (fr)
JP (1) JPH11507517A (fr)
AT (1) ATE232106T1 (fr)
AU (1) AU721624B2 (fr)
CA (1) CA2223153A1 (fr)
DE (1) DE69626132T3 (fr)
WO (1) WO1996039162A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
WO1999052539A1 (fr) 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophane
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
WO2000040725A1 (fr) * 1998-12-28 2000-07-13 Takeda Chemical Industries, Ltd. Methode d'analyse
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
CA2372980A1 (fr) * 1999-05-19 2000-11-23 Astrazeneca Ab Dosages pour agonistes, antagonistes et agonistes inverses d'hormone concentrant la melanine (mch) se liant au recepteur du type somatostatine (slc-1)
AU7315700A (en) * 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
WO2001021169A1 (fr) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone de concentration de la melanine
JP2003522184A (ja) * 2000-02-03 2003-07-22 メルク エンド カムパニー インコーポレーテッド メラニン濃縮ホルモン類似体
US7220720B2 (en) * 2000-02-03 2007-05-22 Merk & Co., Inc. Melanin-concentrating hormone analogs
US6429190B1 (en) 2000-12-15 2002-08-06 Pacifichealth Laboratories, Inc. Method for extending the satiety of food by adding a nutritional composition designed to stimulate cholecystokinin(CCK)
US6809104B2 (en) * 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
EP1485405A4 (fr) * 2001-05-31 2005-09-21 Merck & Co Inc Analogues d'hormones de concentration de la melanine
US7335723B2 (en) * 2001-08-08 2008-02-26 Merck & Co., Inc. Melanin-concentrating hormone antagonists
EP1495046A2 (fr) * 2002-01-09 2005-01-12 Merck & Co., Inc. Agonistes selectifs du recepteur de type 1 de l'hormone de melano-concentration
PL376659A1 (pl) * 2002-11-06 2006-01-09 Tularik Inc. Skondensowane związki heterocykliczne
WO2007100718A2 (fr) 2006-02-24 2007-09-07 Denise Barbut Agonistes des recepteurs de la neurotensine et agonistes des recepteurs des opioides
US20080220104A1 (en) * 2007-03-08 2008-09-11 Cappello John V Compositions for producing satiety
WO2009043527A2 (fr) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
JP4593639B2 (ja) * 2008-03-04 2010-12-08 株式会社マルハニチロ食品 ペプチド含有摂食調節剤
AR096848A1 (es) 2013-07-09 2016-02-03 Takeda Pharmaceuticals Co Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch)
WO2015073878A1 (fr) 2013-11-15 2015-05-21 Ur Diet, Llc Rétroaction biologique de la satiété en temps réel
WO2017103224A1 (fr) * 2015-12-16 2017-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Méthode de traitement de la sclérose latérale amyotrophique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US5049655A (en) * 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
CA2040264A1 (fr) * 1990-04-12 1991-10-13 Tatsuhiko Kanmera Antagonistes de la parathormone

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
Bahjaoui-Bouhaddi et al, Neuropeptides, 1994, 27, 251-258 †
Baker, Trends Endocrinol. Metab., 1994,5, 120-126 †
Bednarek et al, Biochemistry, 2001, 40, 9379-9386 †
Breton et al, Mol. Brain Res., 1993, 18, 297-310 †
DATABASE STN MEDLINE 1 January 1900 (1900-01-01), DROZDZ R ET AL: "Synthesis and iodination of human (phenylalanine 13, tyrosine 19) melanin-concentrating hormone for radioreceptor assay.", XP002108612, Database accession no. 97366174 †
Drodz et al, J. Receptor & Signal Transduction Res., 1995, 15 (1-4), 487-502 †
Fox S. et al, J. Biomolecular Screening 6 (3), 2001, 137-140 †
Ganz et al, J. Physiol. Endocrinol. Metal, 2003, 284, E468-E474 †
Indriati et al, Am. J. Phys. Anthropology, 2001, 114, 242-257 †
J.-L.- NAHON ET AL.: "STRUCTURE AND REGULATION OF THE MELANIN-CONCENTRATING HORMONE GENE.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES., US, vol. 680., 1 January 1993 (1993-01-01), US, pages 111 - 129., XP002108610, ISSN: 0077-8923, DOI: 10.1111/j.1749-6632.1993.tb19678.x †
Ludwig et al, Am. J. Physiol. 274 (Endocrinol. Metab. 37), 1998, E627-E633 †
Luo & Li, Pharmacol. Biochem. & Behaviour, 1991, 38, 495-500 †
Meyers Grosses Taschenlexikon, 1995 †
Miller et al, Peptides, 1993, 14, 413-440 †
Morley, Neuropsychobiology, 1989, 21, 22-30 †
Murray et al, Journal of Neuroendocrinology, 2000, 12, 217-223 †
Poggioli et al, Peptides, 1986, 843-848 †
Rossi et al, Brain Research, 1999, 846, 164-170 †
Tsuji et al, Brain Research Bulletin, 1988, 23, 165-169 †

Also Published As

Publication number Publication date
JPH11507517A (ja) 1999-07-06
AU6041896A (en) 1996-12-24
ATE232106T1 (de) 2003-02-15
EP0871463B1 (fr) 2003-02-05
US20040242487A1 (en) 2004-12-02
CA2223153A1 (fr) 1996-12-12
DE69626132T3 (de) 2008-06-05
DE69626132T2 (de) 2003-12-04
DE69626132D1 (de) 2003-03-13
US5849708A (en) 1998-12-15
EP0871463A1 (fr) 1998-10-21
AU721624B2 (en) 2000-07-13
EP0871463A4 (fr) 1999-09-08
WO1996039162A1 (fr) 1996-12-12

Similar Documents

Publication Publication Date Title
EP0871463B2 (fr) Regulation du comportement alimentaire
EP0988379B1 (fr) Recepteur de ldl
CA2362320A1 (fr) Gene de la calvitie chez l'homme, proteine et utilisations associees
JP2002502251A (ja) ＰＧＣ−１、新規な褐色脂肪ＰＰＡＲ▲下γ▼コアクチベーター
EP0614487A1 (fr) And codant un transporteur de glycine et ses emplois
US7244577B2 (en) Method of screening for modulator of LRP5 activity
US6528634B1 (en) Aiolos gene
AU770018B2 (en) Human N-type calcium channel isoform and uses thereof
WO1997008308A9 (fr) Gene du syndrome de batten-steinert
WO1998046748A1 (fr) Compositions therapeutiques et dosages de diagnostic pour des affections liees a la trbp
WO1997008308A1 (fr) Gene du syndrome de batten-steinert
US5656438A (en) CAIP-like gene family
US5641748A (en) Caip-like gene family
US6682911B1 (en) Laminins and uses thereof
US5837844A (en) CAIP-like gene family
CA2325663A1 (fr) Nouvelles mutations dans le gene freac3 pour le diagnostic et le pronostique du glaucome et de la dysgenesie du segment anterieur
JP2000512506A (ja) 新規化合物
US6818214B2 (en) Two novel genes from psoriatic epidermis: psoriastatin type I and psoriastatin type II
US6423824B1 (en) CAIP-like gene family
US6171800B1 (en) Method of making and binding CAIP polypeptides
US20030013673A1 (en) Modulating the Rad-nm23 interaction
CA2304169A1 (fr) Laminines et leur utilisation
JP2001025389A (ja) Ｔｓａ７００５遺伝子
WO1997049808A1 (fr) Famille de genes du type caip
JP2001078772A (ja) Ｌｕｎｘ遺伝子及び癌微小転移の検出法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990726

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JOSLIN DIABETES CENTER

17Q First examination report despatched

Effective date: 20010129

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

TPAD Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOS TIPA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030205

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030205

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT

Effective date: 20030205

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030205

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030205

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030205

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030205

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030205

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69626132

Country of ref document: DE

Date of ref document: 20030313

Kind code of ref document: P

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20030422

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030505

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030505

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030505

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030605

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030630

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030828

ET Fr: translation filed
PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: JANSSEN PHARMACEUTICA N.V.

Effective date: 20031105

Opponent name: MERCK & CO., INC.

Effective date: 20031104

Opponent name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Effective date: 20031104

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1016512

Country of ref document: HK

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20070731

Year of fee payment: 12

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20071121

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20030606

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20070618

Year of fee payment: 12

ET3 Fr: translation filed ** decision concerning opposition
REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20090228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090101

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090625

Year of fee payment: 14

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100605